Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I-Mab Secures Approval to Conduct Phase 2 Trial of Enoblituzumab Combo Therapy for Solid Tumors in China - Shares Higher

09/28/2021 | 09:08am EST


ę MT Newswires 2021
All news about I-MAB
11/12I MAB : INDEX TO CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
PU
11/12I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2..
PU
11/12I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Anti..
CI
11/10Health Care Stocks Decline Premarket Wednesday
MT
11/10I-Mab Working With Jumpcan Pharmaceutical to Develop, Commercialize Growth Hormone Ther..
MT
11/10I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
PU
11/09I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2..
PR
11/08I-Mab, Roche Diagnostics Start Collaboration to Develop Companion Diagnostics Services
MT
11/08I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Di..
PR
11/08I-Mab and Roche Diagnostics Announces Strategic Collaboration to Co-Develop Companion D..
CI
More news
Analyst Recommendations on I-MAB
More recommendations
Financials (USD)
Sales 2021 84,7 M - -
Net income 2021 -176 M - -
Net cash 2021 589 M - -
P/E ratio 2021 -36,1x
Yield 2021 -
Capitalization 4 864 M 4 864 M -
EV / Sales 2021 50,4x
EV / Sales 2022 23,4x
Nbr of Employees 228
Free-Float 98,2%
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends I-MAB
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 63,20 $
Average target price 96,34 $
Spread / Average Target 52,4%
EPS Revisions
Managers and Directors
Hua Qiong Shen Chief Executive Officer & Director
Zheru Zhang President & Director
John Long Chief Financial Officer
Jing Wu Zang Chairman
Lili Qian Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
I-MAB34.04%4 864
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049